Literature DB >> 22903816

A physiologically-based recirculatory meta-model for nasal fentanyl in man.

Richard N Upton1, David J R Foster, Lona L Christrup, Ola Dale, Kristin Moksnes, Lars Popper.   

Abstract

Pharmacokinetic (PK) and pharmacodynamic (PD) data were available from a study of a nasal delivery system for the opioid analgesic fentanyl, together with data on the kinetics of fentanyl in arterial blood in man, and in the lung and brain of sheep. Our aim was to reconcile these data using a physiologically-based population recirculatory PK-PD model, with emphasis on achieving a meta-model that could simultaneously account for the arterial and venous (arm) concentrations of fentanyl, could relate PD effects (pain scores) to the CNS concentrations of fentanyl, and could account for the effect of body size and age on fentanyl kinetics. Data on the concentration gradients of fentanyl across brain, lung and muscle were used to develop sub-models of fentanyl kinetics in these organs. The sub-models were incorporated into a "whole body" recirculatory model by adding additional sub-models for a venous mixing compartment, the liver and gut, the kidney and the "rest of the body" with blood flows and organ volumes based on values for a Standard Man. Inter-individual variability was achieved by allometric scaling of organ size and blood flows, evidence-based assumptions about the effect of weight and age on cardiac output, and inter-individual variability in the free fraction in plasma and hepatic extraction of fentanyl. Post-operative pain scores were found to be temporally related to the predicted brain concentrations of fentanyl. We conclude that a physiologically-based meta-modelling approach was able to describe clinical PK-PD studies of fentanyl whilst providing a mechanistic interpretation of key aspects of its disposition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22903816     DOI: 10.1007/s10928-012-9268-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  43 in total

1.  The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and target-controlled infusion data.

Authors:  Kenichi Masui; Richard N Upton; Anthony G Doufas; Johan F Coetzee; Tomiei Kazama; Eric P Mortier; Michel M R F Struys
Journal:  Anesth Analg       Date:  2009-10-27       Impact factor: 5.108

2.  Effects of cardiac output on disposition kinetics of sorbitol: recirculatory modelling.

Authors:  M Weiss; G H Hübner; I G Hübner; W Teichmann
Journal:  Br J Clin Pharmacol       Date:  1996-04       Impact factor: 4.335

3.  Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight.

Authors:  G de Simone; R B Devereux; S R Daniels; G Mureddu; M J Roman; T R Kimball; R Greco; S Witt; F Contaldo
Journal:  Circulation       Date:  1997-04-01       Impact factor: 29.690

4.  Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.

Authors:  Trine Andresen; Richard N Upton; David J R Foster; Lona L Christrup; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-12-08       Impact factor: 4.080

5.  A physiologically based, recirculatory model of the kinetics and dynamics of propofol in man.

Authors:  Richard N Upton; Guy Ludbrook
Journal:  Anesthesiology       Date:  2005-08       Impact factor: 7.892

6.  A recirculatory pharmacokinetic model describing the circulatory mixing, tissue distribution and elimination of antipyrine in dogs.

Authors:  T C Krejcie; T K Henthorn; C A Shanks; M J Avram
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

7.  Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.

Authors:  David Foster; Richard Upton; Lona Christrup; Lars Popper
Journal:  Ann Pharmacother       Date:  2008-08-26       Impact factor: 3.154

8.  Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?

Authors:  Kristin Moksnes; Olav M Fredheim; Pål Klepstad; Stein Kaasa; Anders Angelsen; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2008-01-06       Impact factor: 2.953

9.  Pharmacodynamic modeling of thiopental anesthesia.

Authors:  D R Stanski; R J Hudson; T D Homer; L J Saidman; E Meathe
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

Review 10.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

Authors:  Masoud Jamei; Gemma L Dickinson; Amin Rostami-Hodjegan
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

View more
  4 in total

1.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17

2.  Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site.

Authors:  Helen Musther; Katherine L Gill; Manoranjenni Chetty; Amin Rostami-Hodjegan; Malcolm Rowland; Masoud Jamei
Journal:  AAPS J       Date:  2015-06-23       Impact factor: 4.009

3.  Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods.

Authors:  R N Upton; D R Mould
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-01-02

4.  The influence of cardiac output on propofol and fentanyl pharmacokinetics and pharmacodynamics in patients undergoing abdominal aortic surgery.

Authors:  Agnieszka Bienert; Paweł Sobczyński; Katarzyna Młodawska; Roma Hartmann-Sobczyńska; Edmund Grześkowiak; Paweł Wiczling
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-08-25       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.